Mondego Bio kicks off with Series A financing
Lisbon’s immuno-oncology company Mondego Bio Lda has left stealth mode through a Series A financing led by Biovance Capital, supported by OrbiMed and Torrey Pines.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1407 entries already.
Entries by Thomas Gabrielczyk
Roche acquires 89bio for US$3.5bn
/in News/by Thomas GabrielczykRoche has signed a definitive merger agreement to acquire 89bio and its Phase III candidate pegozafermin, an FGF21 analogue for the treatment of moderate to severe metabolic dysfunction-associated steatohepatitis (MASH). The deal is expected to close in Q4 2025.
CSL backs VarmX in US$2.2bn deal
/in News/by Thomas GabrielczykCSL has signed an option and collaboration agreement with VarmX valued at up to US$2.2bn. The company will pay US$117m upfront and will fund a global Phase III trial of VMX-C001.
Enhanced Genomics raises US$19m
/in News/by Thomas GabrielczykBritish Enhanced Genomics Ltd has extended its Series A funding to US$19m. Investors include BGF, Parkwalk, and Meltwind.
Monte Rosa Therapeutics and Novartis agree on second billion-dollar deal
/in News/by Thomas GabrielczykMonte Rosa Therapeutics Inc, founded in Basel in 2018, can look forward to an upfront payment of US$120m for its second collaboration and licensing deal with Novartis AG to develop protein degraders. A total of US$5.7bn is on the table for the new development of an anti-inflammatory candidate that is not part of Monte Rosa’s pipeline.
Trump dismantles FDA expert committees
/in News/by Thomas GabrielczykThe FDA under President Trump is heading for a radical break with decades of practice: the external advisory committees that have long served as critical checks in approval decisions are to be largely sidelined. George Tidmarsh, head of the Centre for Drug Evaluation and Research, has dismissed the panels as redundant and instead wants to rely on the publication of Complete Response Letters (CRLs). Officially, the move is framed as efficiency – in reality, it raises serious questions about the agency’s transparency.
UK pharma lobby warns of crisis in British life sciences
/in News/by Thomas GabrielczykThe Association of the British Pharmaceutical Industry (ABPI) has warned that the UK could miss its target of becoming the number one in European life sciences by 2030.
Alchemab Therapeutics reports US$32m Series A extension
/in News/by Thomas GabrielczykBritish antibody specialist Alchemab Therapeutics Ltd has secured a US$32m Series A extension after it completing preclinical development of ATLX-1282 and starting a Phase I clinical trial.
Servier acquires Kaerus Bioscience’s FXS candidate for US$450m
/in News/by Thomas GabrielczykIn a US$450m deal with UK-based Kaerus Bioscience Ltd, Servier SA has acquired the development and commercialisation rights to KER-0193, a Phase II-ready drug candidate for the treatment of rare Fragile X syndrome, the most common monogenic cause of autism.
NRG Therapeutics Ltd bags £50m in Series B financing
/in News/by Thomas GabrielczykBritish mitochondrial dysfunction specialist NRG Therapeutics Ltd. (“NRG”) has closed an oversubscribed £50m Series B financing. Funds will be used to to achieve clinical proof of concept for NRG5051 in amyotrophic lateral sclerosis (ALS)/motor neurone disease (MND) and to generate Phase Ib data in Parkinson’s disease.